Dear COMPPARE team, participants, stakeholders and friends,
The COMPPARE study has reached an exciting and important phase—thanks to hundreds of prostate cancer patients who chose to participate in this groundbreaking effort.
Funded in 2017 by an $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI), COMPPARE set out to directly compare the benefits and harms of proton therapy versus standard photon radiation therapy in treating prostate cancer. With 2,524 participants enrolled from 51 institutions, this national, patient-centered study is poised to deliver insights that may reshape how prostate cancer is treated for years to come.
In this issue, we invite you to delve further into the importance of our Primary Completion Date (PCD) on February 15, 2026. As we look ahead to this milestone, we also recognize the vital role each participant plays in helping to generate trustworthy, patient-informed results on disease control, side effects, and quality of life. These findings will not only guide physicians and policymakers but also empower future patients to make more informed decisions.
Also in this edition, advances in diagnostic imaging—such as PSMA PET/CT, MRI, and the promising new micro-ultrasound (microUS)—further underscore the importance of improving access, accuracy, and outcomes across the prostate cancer care spectrum. Take a moment to read an important article on this subject from our organizational partner, Brotherhood of the Balloon, in the BOB Tales newsletter.
Your continued participation in follow-up efforts remains critical, as the true impact of treatment is best understood over time. Thank you!
We hope you enjoy a safe and happy summer!
In good health,